Extended Data Fig. 5: RSV pre-F IgG antibody GMC and GMFR through day 361 by treatment and medically attended diagnostic-confirmed infection. | Nature Medicine

Extended Data Fig. 5: RSV pre-F IgG antibody GMC and GMFR through day 361 by treatment and medically attended diagnostic-confirmed infection.

From: Durability of neutralizing RSV antibodies following nirsevimab administration and elicitation of the natural immune response to RSV infection in infants

Extended Data Fig. 5: RSV pre-F IgG antibody GMC and GMFR through day 361 by treatment and medically attended diagnostic-confirmed infection.The alternative text for this image may have been generated using AI.

a, Phase 2b study pre-F antibodies. b, MELODY study pre-F antibodies. n denotes the number of infants at day 361. *P < 0.05, ***P < 0.001, nirsevimab vs placebo with diagnostic confirmed RSV; †††P < 0.001 nirsevimab vs placebo without diagnostic confirmed RSV. Two-sided p-values were calculated based on the F statistic from ANOVA, without adjustment. AU ml-1, arbitrary units per milliliter; BL, baseline; CI, confidence interval; F, fusion protein; GMC, geometric mean concentration; GMFR, geometric mean fold rise; IgG, immunoglobulin G; LLOQ, lower limit of quantification; n, number of infants; RSV, respiratory syncytial virus.

Back to article page